[{"address1": "321 Harrison Avenue", "address2": "Suite 900", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 949 2643", "website": "https://www.monterosatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 129, "companyOfficers": [{"maxAge": 1, "name": "Dr. Markus  Warmuth M.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 924600, "exercisedValue": 0, "unexercisedValue": 2041632}, {"maxAge": 1, "name": "Dr. Filip  Janku M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 713200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Champoux", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Castle Ph.D.", "age": 51, "title": "Chief Data & Information Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Townson Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Funderburk", "title": "Senior VP and Head of IR & Strategic Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nickson J.D., Ph.D.", "age": 44, "title": "Chief Business & Legal Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Magnus  Walter DPHIL", "title": "Senior Vice President of Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Dunn", "age": 57, "title": "Vice President & Corporate Controller", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.53, "open": 5.82, "dayLow": 5.26, "dayHigh": 6.545, "regularMarketPreviousClose": 6.53, "regularMarketOpen": 5.82, "regularMarketDayLow": 5.26, "regularMarketDayHigh": 6.545, "beta": 1.388, "forwardPE": -3.0106952, "volume": 405996, "regularMarketVolume": 405996, "averageVolume": 232217, "averageVolume10days": 202180, "averageDailyVolume10Day": 202180, "bid": 5.59, "ask": 5.69, "bidSize": 200, "askSize": 100, "marketCap": 345528864, "fiftyTwoWeekLow": 2.44, "fiftyTwoWeekHigh": 8.84, "priceToSalesTrailing12Months": 59.998066, "fiftyDayAverage": 4.2394, "twoHundredDayAverage": 5.011475, "currency": "USD", "enterpriseValue": 127650072, "floatShares": 34896634, "sharesOutstanding": 61372800, "sharesShort": 2779929, "sharesShortPriorMonth": 2559406, "sharesShortPreviousMonthDate": 1719532800, "dateShortInterest": 1722384000, "sharesPercentSharesOut": 0.045300003, "heldPercentInsiders": 0.0070700003, "heldPercentInstitutions": 0.89536005, "shortRatio": 12.24, "shortPercentOfFloat": 0.0829, "impliedSharesOutstanding": 61372800, "bookValue": 3.664, "priceToBook": 1.5365721, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -130414000, "trailingEps": -2.22, "forwardEps": -1.87, "enterpriseToRevenue": 22.165, "enterpriseToEbitda": -0.969, "52WeekChange": -0.06322795, "SandP52WeekChange": 0.2644137, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GLUE", "underlyingSymbol": "GLUE", "shortName": "Monte Rosa Therapeutics, Inc.", "longName": "Monte Rosa Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624541400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e1526429-092c-3bce-8f14-de475e92b666", "messageBoardId": "finmb_690261281", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.63, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.83, "targetMedianPrice": 16.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 262204992, "totalCashPerShare": 4.273, "ebitda": -131783000, "totalDebt": 44356000, "quickRatio": 6.424, "currentRatio": 6.562, "totalRevenue": 5759000, "debtToEquity": 19.743, "revenuePerShare": 0.097, "returnOnAssets": -0.27986, "returnOnEquity": -0.59506, "freeCashflow": -57035500, "operatingCashflow": -61004000, "grossMargins": 1.0, "operatingMargins": -6.9525, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-23"}]